The controversial diet that restarts kidney function in 3 months

[ad_1]

A controversial diet touted as top for weight loss may help people with the most common inherited kidney disease that accounts for 10% of kidney failure cases

Possible nutritional treatment could be the ketogenic diet for people with Autosomal Dominant Polycystic Kidney Disease (ADPKD)the most common hereditary nephropathy responsible for 10% of renal failure cases.

The above was concluded by researchers led by Dr. Roman-Ulrich Müller from the University Hospital of Cologne and the Aging Research Excellence Cluster CECAD research center, whose findings are published in the scientific journal Cell Reports Medicine. In November 2022, Dr. Müller presented the preliminary findings at the American Society of Nephrology’s Kidney Week.

Results in three months

The 66 patients who participated in the study were divided into three groups, one of which followed ketogenic diet -mostly fat, less protein and minimal carbohydrates- for three months, one group water fasting -only water allowed- for three days each month and one that remained within official dietary recommendations such as starchy foods, lots of fruit and vegetables and good sources of protein.

Against researchers’ reservations95% of ketogenic diet participants and 85% of the water fasts stated that adherence to the new diet plan was achievable. For the first group, the researchers measured ketone bodies (alternative energy sources instead of glucose) in the blood samples to see if they had actually followed the guidelines.

In just three months, according to the results, statistically significant were observed positive changes in nodal parameters such as kidney function, without unexpected side effects.

One step closer to a cure

It is important that this is a dietary pattern that can be adopted by patients, as long as it is enough to forget bread and sweets and increase consumption of olive oil and fatty fish such as salmon, explains Dr. Müller who characterizes the findings important step in the development of a potential new treatment against ADPKD.

Currently, with the data coming from phase II clinical trial, it is not possible to formulate relevant dietary recommendations. This does not negate the importance of the study, whose design in clinical trial standards for drugs reinforces the validity of its findings and confirms that “could be the starting point for many nutritional treatment strategies“, according to the professor.

Leave a Comment